Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Risperdal Goes Generic, Antipsychotics Seek To Differentiate Themselves

Executive Summary

Johnson & Johnson and other manufacturers of atypical antipsychotics face erosion of their market share with FDA's approval of the first generic version of J&J's Risperdal (risperidone). But they may ward off competition by emphasizing the differences between their products and the first generic among the newer antipsychotics
Advertisement

Related Content

Seroquel XR Needs Long-Term Safety Data For Depression, Anxiety Monotherapy – FDA Panel
Teva Loses Exclusivity For Generic Risperdal; Mylan To Launch Its Product
Teva Loses Exclusivity For Generic Risperdal; Mylan To Launch Its Product
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
Advertisement
UsernamePublicRestriction

Register

PS049828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel